Stämm, a biopharmaceutical manufacturer based in Argentina, has announced a strategic collaboration with cultivated chicken producer SuperMeat to enhance biomanufacturing processes for cultivated meat.

This partnership, supported by mutual investor Varana Capital, aims to benchmark and integrate Stämm’s continuous bioprocessing technology into SuperMeat's production framework.

The collaboration will leverage Stämm's advanced Bioprocessor technology, which has demonstrated significant cost reductions and increased productivity in pharmaceutical applications. The Bioprocessor is an automated, continuous, bubble-free bioreactor designed to optimise muscle fibre growth and enhance the formation of adipocytes, crucial for developing whole-cut cultivated meat products.

SuperMeat has recently achieved a milestone by lowering the cost of cultivated chicken production to $11.79 per pound, a critical threshold for market competitiveness. The partnership aims to further refine this process, potentially increasing product mass and improving the structural and flavour profiles of cultivated meat.

A joint team from both companies will conduct a pilot program at SuperMeat's facility, focusing on the integration of Stämm's Bioprocessor into the existing production line.

Yuyo Llamazares Vegh, CEO of Stämm, said: "In the coming months, a joint team will benchmark and evaluate how to integrate our Bioprocessor into SuperMeat's end-to-end production process. We are excited to see the results of this unique alliance."

Ido Savir, CEO of SuperMeat, added: "This partnership demonstrates how complementary technologies can combine to drive progress in the cultivated meat industry. By uniting our technologies, we create a pathway to whole cut cultivated meat products that deliver superior quality and consumer appeal."

The collaborative efforts will not only focus on product development but also on creating a scalable model for future production and economic viability.

The alternative protein market is projected to reach up to $290 billion by 2035, according to a report by BCG and Blue Horizon. This growth presents substantial business opportunities for companies operating within the cultivated meat sector.

Ezra Gardner, co-founder and CIO of Varana Capital, noted that Israel’s robust entrepreneurial environment makes it an ideal location for advancing innovations in alternative protein production.

"Israel's exceptional entrepreneurial spirit and technological prowess make it an ideal investment destination for advancing the revolution in alternative protein production, both by introducing Stamm's biomanufacturing innovation into its ecosystem and by combining it with Supermeat's ingenuity," he commented.

#Stamm #SuperMeat #Israel #Argentina #biomanufacturing #cultivatedmeat #chicken